Neoadjuvant immunotherapy: is this the “new” induction chemotherapy?

Immunotherapy is rapidly becoming another option for the treatment of cancer of the head and neck. Harnessing the immune system with immune checkpoint inhibitors, co-stimulatory agonists, vaccines, toll-like receptor (TLR) inhibitors, and chimeric antigen receptor (CAR) T cells, has shown clinical benefit in various types of cancer.1,2

https://ift.tt/2Xtnv7o